NCT02845596 is a NA clinical trial of cyclosporine in Severe Aplastic Anemia, sponsored by Michael Pulsipher.

Who is sponsoring NCT02845596?

NCT02845596 is sponsored by Michael Pulsipher.

What drugs are being tested in NCT02845596?

Interventions in NCT02845596: cyclosporine, Matched Unrelated Donor Hematopoietic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), rabbit anti-thymocyte globulin (ATG), methotrexate, fludarabine, cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST).

What condition does NCT02845596 study?

NCT02845596 studies Severe Aplastic Anemia.

Is NCT02845596 still recruiting?

NCT02845596 is currently completed. Last updated 6 May 2025.

Last reviewed 2025-05-06 · How we verify

NCT02845596

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Completed NA Last updated 6 May 2025

What this trial tests

NA trial testing cyclosporine in Severe Aplastic Anemia in 40 participants. Completed in 19 July 2023.

Timeline

1 August 2016

Primary endpoint
3 November 2020

19 July 2023

Quick facts

Lead sponsor	Michael Pulsipher
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	40
Start date	1 August 2016
Primary completion	3 November 2020
Estimated completion	19 July 2023
Sites	13 locations across United States

Drugs / interventions tested

cyclosporine (cyclosporine) — full drug profile →
Matched Unrelated Donor Hematopoietic Stem Cell Transplant
horse anti-thymocyte globulin (ATG)
rabbit anti-thymocyte globulin (ATG) — full drug profile →
methotrexate
fludarabine (FLUDARABINE) — full drug profile →
cyclophosphamide (cyclophosphamide) — full drug profile →
low-dose total body irradiation (TBI)
Immunosuppressive Therapy (IST) — full drug profile →

Conditions studied

Severe Aplastic Anemia — all drugs for Severe Aplastic Anemia →

Sponsor

Michael Pulsipher — full company profile →

Who can join

Under 25, any sex, with Severe Aplastic Anemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of patients randomized to HSCT that actually complete HSCT
Time frame: 4 years
Feasibility of comparing outcomes of patients treated de novo with IST versus matched unrelated donor HSCT for pediatric acquired severe aplastic anemia as defined by percentage of patients randomized to HSCT that actually complete HSCT.

Sponsor's own description

The purpose of this study is to determine the feasibility of comparing outcomes of patients treated de novo with immunosuppressive therapy (IST) versus matched unrelated donor (MUD) hematopoietic stem cell transplant (HSCT) for pediatric acquired severe aplastic anemia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.
Georges GE, Doney K, Storb R. · · 2018 · cited 91× · PMID 30108110 · DOI 10.1182/bloodadvances.2018021162
Future directions in transplantation for aplastic anemia.
Sharma A. · · 2025 · PMID 41348014 · DOI 10.1182/hematology.2025000767

Verify or expand the search:

Other trials of cyclosporine

Trials testing the same drug.

NCT06837259 — A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study · Phase 1 · completed
NCT06642909 — A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy · Phase 2 · active not recruiting
NCT06509243 — Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis · NA · completed
NCT04979884 — Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital · Phase 3 · completed
NCT04743739 — Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN · Phase 3 · terminated

Other recruiting trials for Severe Aplastic Anemia

Currently open trials in the same condition.

NCT06622694 — CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia · Phase 1 · recruiting
NCT06517641 — Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia · Phase 2 · recruiting
NCT06695741 — Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia · Phase 2 · recruiting
NCT06412497 — MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Se · Phase 2 · recruiting
NCT06378060 — Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02845596 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Michael Pulsipher
Last refreshed: 6 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02845596.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing